Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Siponimod in Polymyositis
NCT01801917Phase 2Terminated
- Sponsor
- Novartis
- Start
- Apr 2013
- Primary completion
- Aug 2016
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial of siponimod in polymyositis (PM) (3 arms), sponsored by Novartis. Primary endpoints: Manual Muscle Testing in 24 Muscles at 12 weeks and Serum Creatine Kinase at 12 weeks. Started Apr 2013; status: terminated.
02
Drugs
siponimod
03
Conditions
polymyositis (PM)
Beyond the preview
Go deeper on NCT01801917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01801917.